ANNEXA-4: Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis
BMC Critical Care
OS Costa, SJ Connolly, M Sharma, J Beyer-Westendorf, MJ Christoph, B Lovelace, CI Coleman
June 2022
